Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection

A new coronavirus associated with human respiratory disease in China

(2020) Fan Wu et al.   NATURE

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Charting the Fragmented Landscape of Drug Synergy

(2020) Christian T. Meyer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

SARS-CoV-2 Vaccines: Status Report

(2020) Fatima Amanat et al.   IMMUNITY

The COVID-19 vaccine development landscape

(2020) Tung Thanh Le et al.   NATURE REVIEWS DRUG DISCOVERY

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

(2020) Shutoku Matsuyama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

(2020) Cynthia Liu et al.   ACS Central Science

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

(2020) Yadi Zhou et al.   Cell Discovery

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)

(2020) Rui-fang Zhu et al.   Journal of Translational Medicine

TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection

(2019) Naoko Iwata-Yoshikawa et al.   JOURNAL OF VIROLOGY

Quantifying Drug Combination Synergy along Potency and Efficacy Axes

(2019) Christian T. Meyer et al.   Cell Systems

Building a mechanistic mathematical model of hepatitis C virus entry

(2019) Mphatso Kalemera et al.   PLoS Computational Biology

Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors

(2019) Yang Jiang et al.   PROCESS BIOCHEMISTRY

You Cannot Have Your Synergy and Efficacy Too

(2019) Pramita Sen et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

(2018) Kazuya Shirato et al.   VIROLOGY

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents

(2018) Vipul Gupta et al.   PLoS Computational Biology

Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection

(2018) Vishnu Venugopal et al.   PLoS Computational Biology

Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era

(2018) Rubesh Raja et al.   IMMUNOLOGICAL REVIEWS

Investigating Different Mechanisms of Action in Combination Therapy for Influenza

(2018) Kelli Melville et al.   Frontiers in Pharmacology

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations

(2017) Pranesh Padmanabhan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Future of Cysteine Cathepsins in Disease Management

(2017) Lovro Kramer et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters

(2017) Oliver F. Brandenberg et al.   PLoS Pathogens

Cathepsin B and L inhibitors: a patent review (2010 - present)

(2016) Yu-Yao Li et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

SARS and MERS: recent insights into emerging coronaviruses

(2016) Emmie de Wit et al.   NATURE REVIEWS MICROBIOLOGY

Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models

(2016) Desiree Y. Baeder et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Protease inhibitors targeting coronavirus and filovirus entry

(2015) Yanchen Zhou et al.   ANTIVIRAL RESEARCH

The HIV-1 Entry Process: A Stoichiometric View

(2015) Oliver F. Brandenberg et al.   TRENDS IN MICROBIOLOGY

Modeling Influenza Virus Infection: A Roadmap for Influenza Research

(2015) Alessandro Boianelli et al.   Viruses-Basel

Mathematical model of adherent Vero cell growth and poliovirus production in animal component free medium

(2014) Ramona V. Ursache et al.   BIOPROCESS AND BIOSYSTEMS ENGINEERING

Quantitative Evaluation and Optimization of Co-drugging to Improve Anti-HIV Latency Therapy

(2014) Victor C. Wong et al.   Cellular and Molecular Bioengineering

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

(2014) Fei Xiao et al.   GUT

Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment

(2014) Pranesh Padmanabhan et al.   Nature Communications

Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2

(2013) Kazuya Shirato et al.   JOURNAL OF VIROLOGY

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE

Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry

(2012) M. Kawase et al.   JOURNAL OF VIROLOGY

A quantitative basis for antiretroviral therapy for HIV-1 infection

(2012) Benjamin L Jilek et al.   NATURE MEDICINE

Viral Kinetics Suggests a Reconciliation of the Disparate Observations of the Modulation of Claudin-1 Expression on Cells Exposed to Hepatitis C Virus

(2012) Pranesh Padmanabhan et al.   PLoS One

Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response

(2011) I. Glowacka et al.   JOURNAL OF VIROLOGY

Estimating the Threshold Surface Density of Gp120-CCR5 Complexes Necessary for HIV-1 Envelope-Mediated Cell-Cell Fusion

(2011) Shiva Naresh Mulampaka et al.   PLoS One

A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs

(2011) L. Shen et al.   Science Translational Medicine

Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry

(2011) Pranesh Padmanabhan et al.   PLoS Computational Biology

A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry

(2010) A. Shulla et al.   JOURNAL OF VIROLOGY

Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2

(2010) S. Matsuyama et al.   JOURNAL OF VIROLOGY

Modeling amantadine treatment of influenza A virus in vitro

(2008) Catherine A.A. Beauchemin et al.   JOURNAL OF THEORETICAL BIOLOGY

A methodology for performing global uncertainty and sensitivity analysis in systems biology

(2008) Simeone Marino et al.   JOURNAL OF THEORETICAL BIOLOGY

Estimating the Stoichiometry of Human Immunodeficiency Virus Entry

(2008) C. Magnus et al.   JOURNAL OF VIROLOGY